Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,354.00
Bid: 12,352.00
Ask: 12,354.00
Change: -44.00 (-0.35%)
Spread: 2.00 (0.016%)
Open: 12,432.00
High: 12,482.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Europe's STOXX 600 marks third month of gains on earnings, recovery hopes

Fri, 30th Apr 2021 09:54

* AstraZeneca boosts UK's FTSE 100

* Barclays tumbles despite profit beat

* STOXX 600 chalks up 1.8% rise in April

* European economy dips into second technical recession in
Q1
(Updates to market close)

By Sruthi Shankar and Ambar Warrick

April 30 (Reuters) - European stocks ended lower on Friday
after dismal GDP data, but marked a third straight month of
gains on strong corporate earnings and optimism about an
economic recovery from the COVID-19 pandemic.

The pan-regional STOXX 600 index fell 0.3%,
hovering below its all-time high, and ending the month 1.8%
higher.

Data showed the euro zone economy dipped into a second
technical recession after a smaller than expected contraction in
the first quarter, but is now set for recovery as pandemic curbs
are lifted amid accelerating vaccination campaigns.

The German economy contracted by a greater-than-expected
1.7%, hit by renewed lockdowns, while the French economy grew
more than expected.

But strong earnings showed companies in the euro zone were
well on their way to recover from the impact of the pandemic.

AstraZeneca jumped 4.3% as the British drugmaker
posted better-than-expected results and forecast second half
growth.

Swedish Match rose 0.7% after the tobacco group
reported a much higher first-quarter operating profit than
expected, helped by growth in its Smokefree product segment. UK
peers British American Tobacco and Imperial Brands
rose more than 2% each.

Broadly, European earnings have come in much stronger than
expected, with a higher than usual 71% of companies beating
profit expectations in the first quarter, according to Refinitiv
IBES data. A third of STOXX 600 companies have published results
so far.

"Expectations are high, companies are beating even these
elevated expectations, and yet the market is responding with
caution," Lewis Grant, portfolio manager at Federated Hermes,
wrote in a note.

"At current valuations, and with much pandemic related
uncertainty remaining, many investors are more concerned about
downside than upside."

Strong earnings from British firms helped the European
retailers sector outpace its peers in April with a 6.7%
bounce, while automobile stocks lagged as a global
semiconductor shortage hurt production.

Banking stocks came under pressure on Friday as euro
zone bond yields eased from their highest level since January
2020. But the sector raced past its peers this week with a near
6% gain, driven by a swathe of strong earnings.

Barclays tumbled 7% despite reporting a quarterly
profit that more than doubled, while France's BNP Paribas
slipped 0.8% on higher costs.

Spain's Banco Sabadell jumped 8.7% to the top of
the STOXX 600 after its quarterly profit beat market
expectations, helped by strength in its British unit TSB.
(Reporting by Sruthi Shankar in Bengaluru; Editing by Shounak
Dasgupta and Mark Potter)

More News
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.